← Leaderboards
Douglas R Galasko
University Of California San Diego
$47,442,835
Attributed
$55,560,185
Total exposure
22
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$95,100,188 · 24
By mechanism
P50$42,616,636 · 6
P01$18,332,029 · 6
U01$14,807,579 · 4
R01$9,395,554 · 3
P30$7,931,621 · 3
U19$1,706,769 · 1
Top collaborators
- James Bruce Leverenz4 shared
- Oscar L. Lopez4 shared
- Steven Lee Wagner2 shared
- Kevin D Rynearson1 shared
Most similar at University Of California San Diego
Same institution · by research overlap
- Edward H. Koo$17,601,880
- Igor Grant$65,384,704
- Leon J Thal$9,971,967
- Terry L Jernigan$37,204,806
- Michael W Kalichman$1,111,266
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePlasmaDementiaPathologyCognitionSamplingCognitiveClinical ResearchBiological MarkersProgramsAgingResearch PersonnelElderlyFundingLeadBrainMild Cognitive ImpairmentDiagnosisInnovationTau ProteinsCohortNeuropathologyAutopsy
Grant awards (87)
In vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate safety of GSM-779690$1,612,640
U01 · FY2025 · AG · contact PI
Dementia with Lewy Bodies Consortium$1,215,498
U01 · FY2025 · NS
Core B: Clinical Core$902,942
P30 · FY2025 · AG · contact PI
Core F: Biomarker Core$395,441
P30 · FY2025 · AG · contact PI
Dementia with Lewy Bodies Consortium$2,250,274
U01 · FY2024 · NS
Core B: Clinical Core$965,032
P30 · FY2024 · AG · contact PI
Core F: Biomarker Core$481,887
P30 · FY2024 · AG · contact PI
Dementia with Lewy Bodies Consortium$2,127,650
U01 · FY2023 · NS
Clinical Core$997,140
P30 · FY2023 · AG · contact PI
A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects$2,522,029
R01 · FY2022 · AG · contact PI
Dementia with Lewy Bodies Consortium$2,091,032
U01 · FY2022 · NS
Clinical Core$1,148,328
P30 · FY2022 · AG · contact PI
Comparative Study of Molecular Signatures in HIV-Related Neuropathogenesis and Alzheimer's Disease$789,998
R01 · FY2022 · AG · contact PI
A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects$3,156,733
R01 · FY2021 · AG
Clinical Core$1,050,259
P30 · FY2021 · AG · contact PI
Comparative Study of Molecular Signatures in HIV-Related Neuropathogenesis and Alzheimer's Disease$789,791
R01 · FY2021 · AG · contact PI
Clinical Core$995,559
P30 · FY2020 · AG · contact PI
Clinical Core$995,033
P30 · FY2019 · AG · contact PI
CSF SAMPLING STUDY$863,645
U19 · FY2019 · AG · contact PI
Clinical Core$974,231
P50 · FY2018 · AG · contact PI
Core A: Administrative Core$701,507
P50 · FY2018 · AG · contact PI
Clinical Core$974,596
P50 · FY2017 · AG · contact PI
Core A: Administrative Core$701,766
P50 · FY2017 · AG · contact PI
Clinical Core$926,874
P50 · FY2016 · AG · contact PI
Core A: Administrative Core$668,095
P50 · FY2016 · AG · contact PI
UCSD Alzheimer's Disease Research Center P50$2,919,722
P50 · FY2015 · AG · contact PI
Clinical Core$904,344
P50 · FY2015 · AG · contact PI
Core A: Administrative Core$642,584
P50 · FY2015 · AG · contact PI
CSF SAMPLING STUDY$270,890
U19 · FY2015 · AG · contact PI
UCSD Alzheimer's Disease Research Center P50$3,174,023
P50 · FY2014 · AG · contact PI
Clinical Core$926,874
P50 · FY2014 · AG · contact PI
Core A: Administrative Core$668,094
P50 · FY2014 · AG · contact PI
CSF SAMPLING STUDY$572,234
U19 · FY2014 · AG · contact PI
Translational Center for Alzheimer's Disease Target and Drug Discovery$310,000
R34 · FY2014 · AG · contact PI
Alzheimer's Disease Research Center$2,723,870
P50 · FY2013 · AG · contact PI
Clinical Core B$886,843
P50 · FY2013 · AG · contact PI
Administrative Core A$628,934
P50 · FY2013 · AG · contact PI
CLINICAL STUDIES OF NSAIDSs AS y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE$559,314
P01 · FY2013 · AG · contact PI
Alzheimer's Disease Research Center$2,922,029
P50 · FY2012 · AG · contact PI
Clinical Core B$1,004,721
P50 · FY2012 · AG · contact PI
Administrative Core A$717,723
P50 · FY2012 · AG · contact PI
CLINICAL STUDIES OF NSAIDSs AS y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE$385,879
P01 · FY2012 · AG · contact PI
Alzheimer's Disease Research Center$2,930,762
P50 · FY2011 · AG · contact PI
Clinical Core B$947,577
P50 · FY2011 · AG · contact PI
CLINICAL STUDIES OF NSAIDSs AS y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE$749,734
P01 · FY2011 · AG · contact PI
Administrative Core A$683,289
P50 · FY2011 · AG · contact PI
Alzheimer's Disease Research Center$2,969,448
P50 · FY2010 · AG · contact PI
Clinical Core B$956,997
P50 · FY2010 · AG · contact PI
Administrative Core A$695,650
P50 · FY2010 · AG · contact PI
CLINICAL STUDIES OF NSAIDSs AS y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE$624,949
P01 · FY2010 · AG · contact PI
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD$488,012
U01 · FY2010 · AG · contact PI
Alzheimer's Disease Research Center$2,916,244
P50 · FY2009 · AG · contact PI
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD$1,362,818
U01 · FY2009 · AG · contact PI
Clinical Core B$938,339
P50 · FY2009 · AG · contact PI
Administrative Core A$686,541
P50 · FY2009 · AG · contact PI
CLINICAL STUDIES OF NSAIDSs AS y-SECRETASE MODULATORS IN ALZHEIMER'S DISEASE$588,879
P01 · FY2009 · AG · contact PI
Alzheimer's Disease Research Center$2,793,031
P50 · FY2008 · AG · contact PI
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD$1,517,318
U01 · FY2008 · AG · contact PI
TESTING THE ROLE OF AXONAL TRANSPORT DISTURBANCE IN AD?$192,910
P50 · FY2008 · AG · contact PI
Alzheimer's Disease Research Center$2,679,551
P50 · FY2007 · AG · contact PI
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD$1,543,069
U01 · FY2007 · AG · contact PI
Biomarkers in Aging, MCI and Alzheimer's Disease$404,619
R01 · FY2007 · AG · contact PI
Alzheimer's Disease Research Center$80,388
P50 · FY2007 · AG · contact PI
Alzheimer's Disease Research Center$79,079
P50 · FY2007 · AG · contact PI
Age related neurodegenerative diseases in Micronesia$1,955,033
P01 · FY2006 · AG · contact PI
CORE--CLINICAL$783,410
P01 · FY2006 · AG · contact PI
A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD$599,268
U01 · FY2006 · AG · contact PI
Biomarkers in Aging, MCI and Alzheimer's Disease$416,703
R01 · FY2006 · AG · contact PI
CORE---ADMINISTRATIVE, DATABASE, AND STATISTICAL$177,099
P01 · FY2006 · AG · contact PI
PREVALENCE /INCIDENCE /RISK FACTORS FOR DEMENTIA ON GUAM$89,002
P01 · FY2006 · AG · contact PI
Age related neurodegenerative diseases in Micronesia$1,959,885
P01 · FY2005 · AG
Biomarkers in Aging, MCI and Alzheimer's Disease$426,731
R01 · FY2005 · AG
Age related neurodegenerative diseases in Micronesia$1,917,227
P01 · FY2004 · AG
Biomarkers in Aging, MCI and Alzheimer's Disease$426,731
R01 · FY2004 · AG
Age related neurodegenerative diseases in Micronesia$1,871,544
P01 · FY2003 · AG
Biomarkers in Aging, MCI and Alzheimer's Disease$462,219
R01 · FY2003 · AG
Age related neurodegenerative diseases in Micronesia$53,737
P01 · FY2003 · AG
Age related neurodegenerative diseases in Micronesia$1,901,170
P01 · FY2002 · AG
CORE--CLINICAL$751,524
P01 · FY2002 · AG
CORE---ADMINISTRATIVE, DATABASE, AND STATISTICAL$177,940
P01 · FY2002 · AG
PREVALENCE /INCIDENCE /RISK FACTORS FOR DEMENTIA ON GUAM$92,443
P01 · FY2002 · AG
A PHASE 1B STUDY OF IPA IN AD$0
U01 · FY2002 · AG
A PHASE 1B STUDY OF IPA IN AD$0
U01 · FY2002 · AG
CLINICAL EVALUATION OF NSAIDS AS ANTI-AMYLOID COMPOUNDS$0
P01 · FY2002 · AG
AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA$1,859,796
P01 · FY2001 · AG
A PHASE 1B STUDY OF IPA IN AD$0
U01 · FY2001 · AG
AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA$1,833,464
P01 · FY2000 · AG